| Title |
|
Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
10.1016/j.clml.2022.11.010 |
|
|
| Abstract |
|
In patients with relapsed/refractory lymphoma after first line therapy, chemosensitivity to salvage chemotherapy is the main determinant of outcome pre-autologous stem cell transplant . With novel therapies not yet widely available and poor responses to conventional dose salvage therapy such as ifosfamide, carboplatin, and etoposide (ICE) in patients with early relapse within 12 months and primary refractory disease, there is capacity to dose intensify ifosfamide and etoposide (augmented ICE). |
|
|
| Link |
|
| Citation |
|
Clinical Lymphoma, Myeloma & Leukemia 2023; 23(3) |
|
|
| Jornal Title |
|
Clinical lymphoma, myeloma & leukemia |
|
|
| ISSN |
|
